Stromal tumor-infiltrating lymphocytes (TILs), although not assessed in our cohort, have emerged as validated predictive and prognostic biomarkers, particularly in TNBC and increasingly in HER2-positive disease [11,12,13]. This evidence concerns the gene ERBB2 and neoplasm.